KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pfizer (PFE) Tax Provisions (2016 - 2026)

Pfizer has reported Tax Provisions over the past 18 years, most recently at $461.0 million for Q1 2026.

  • Quarterly Tax Provisions rose 343.92% to $461.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $384.0 million through Mar 2026, up 88.24% year-over-year, with the annual reading at -$266.0 million for FY2025, 850.0% down from the prior year.
  • Tax Provisions was $461.0 million for Q1 2026 at Pfizer, up from -$2.0 million in the prior quarter.
  • Over five years, Tax Provisions peaked at $1.6 billion in Q3 2022 and troughed at -$964.0 million in Q4 2023.
  • The 5-year median for Tax Provisions is $141.0 million (2025), against an average of $172.4 million.
  • Year-over-year, Tax Provisions plummeted 370.79% in 2023 and then skyrocketed 343.92% in 2026.
  • A 5-year view of Tax Provisions shows it stood at $356.0 million in 2022, then tumbled by 319.1% to -$780.0 million in 2023, then soared by 130.0% to $234.0 million in 2024, then crashed by 100.85% to -$2.0 million in 2025, then soared by 23150.0% to $461.0 million in 2026.
  • Per Business Quant, the three most recent readings for PFE's Tax Provisions are $461.0 million (Q1 2026), -$2.0 million (Q4 2025), and -$216.0 million (Q3 2025).